Development of novel therapeutic antibody approach being evaluated in clinical trials for patients with multiple myeloma

MorphoSys will hold a conference call on Thursday, June 27, at 4:00pm CEST (3:00pm GMT/10:00am EDT)

  • Celgene secures worldwide rights to MOR202, whereby the companies will jointly develop MOR202 globally and co-promote the product in Europe
  • MorphoSys retains a 50/50 profit sharing in its co-promotion territory and is eligible to receive tiered double-digit royalties outside of the co-promotion territory

Morphosys (TG:MOR)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Morphosys Charts.
Morphosys (TG:MOR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Morphosys Charts.